SavedAdd your journal

Journals / Dicle Üniversitesi Veteriner Fakültesi Dergisi / 2017 / Cilt: 10 Sayı: 2

N-asetil-L-Sisteinin Ekstramukolitik Etkileri

Devran Coşkun(SİİRT ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ, KLİNİK ÖNCESİ BİLİMLERİ BÖLÜMÜ, VETERİNERLİK FARMAKOLOJİ VE TOKSİKOLOJİSİ ANABİLİM DALI)
Pages
154–162
Publication Date
2017-12-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Özellikle merkezi sinir sistemi ve antioksidan etkilerinin sayesinde klinikte birçok hastalıkta kullanılabileceği ve asıl tedaviye destek amaçlı kullanılabileceği anlatılmıştır. 

📌 3 Key Takeaways

🎯
Objective & Hypothesis:N-asetil-L-sistein, mukolitik ve ekspektoran etkisi oldukça belirgin bir solunum sistemi ilacıdır.
📊
Key Findings & Data:Bu etkileri sayesinde solunum sistemi enfeksiyonlarında sıklıkla reçete edilmektedir.
💡
Conclusion & Impact:Özellikle merkezi sinir sistemi ve antioksidan etkilerinin sayesinde klinikte birçok hastalıkta kullanılabileceği ve asıl tedaviye destek amaçlı kullanılabileceği anlatılmıştır. 
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:N-asetil-L-sistein · ekstramukolitik

Özet

N-asetil-L-sistein, mukolitik ve ekspektoran etkisi oldukça belirgin bir solunum sistemi ilacıdır. Bu etkileri sayesinde solunum sistemi enfeksiyonlarında sıklıkla reçete edilmektedir. Yapılan araştırmalarda ise N-asetil-L-sisteinin solunum sistemi dışında birçok vakada faydalı etkileri belirlenmiştir. Bu derlemede N-asetil-L-sisteinin kullanıldığı farklı hastalıklar ve farklı etki mekanizmaları hakkında bilgi verilmiştir. Özellikle merkezi sinir sistemi ve antioksidan etkilerinin sayesinde klinikte birçok hastalıkta kullanılabileceği ve asıl tedaviye destek amaçlı kullanılabileceği anlatılmıştır. 

🔖

Cite This Article

Coşkun, D. (2017). N-asetil-L-Sisteinin Ekstramukolitik Etkileri. Dicle Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 10 Sayı: 2, 154–162. https://ajindex.com/articles/1201837

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (67)

  1. Dhar R. (2013). Role of mucolytics in wet cough. J Assoc Physicians India. 61: 23-27.
  2. Malerba M, Ragnoli B. (2008). Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Met. 4(8): 1119-1129.
  3. Kayaalp O. (1995). Tıbbi Farmakoloji Bölüm 5: Solunum sistemi ile İlgili Bazı İlaçlar. 7. baskı. 1558-1563. Feryal Matbaacılık San ve Tic. Ltd. Şti. Ankara.
  4. Samuni Y, Goldstein S, Dean OM, Berk M. (2013). The chemistry and biological activities of N-acetylcysteine. Biochimica et Biophysica Acta (BBA)-General Subjects. 1830 (8): 4117-4129.
  5. EMA. http://www.ema.europa.eu/docs/en_GB/document_library/ Maximum_Residue_Limits Report/2009/11/WC500009290.pdf. Erişim tarihi:10.05.2017.
  6. Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. (2014). N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain and behavior. 4(2): 108-122.
  7. Echevarria MAN, Reis TA, Capatti GR et al. (2017). N-acetylcysteine for treating cocaine addiction–A systematic review. Psychiatry Research. 251: 197–203
  8. Moussawi K, Pacchioni A, Moran M et al. (2009). N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat. Neurosci. 12(2): 182-189.
  9. Dean O, Giorlando F, Berk M. (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. JPN. 36(2): 78.
  10. Heard K, Green J. (2012). Acetylcysteine therapy for acetaminophen poisoning. Curr Pharm Biotechnol. 13(10): 1917-1923.
  11. Ritter C, Andrades ME, Reinke A et al. (2004). Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Critical care medicine. 32(2): 342-349.
  12. Feldman L, Sherman RA, Weissgarten J. (2012). N-Acetylcysteine Use for Amelioration of Aminoglycoside Induced Ototoxicity in Dialysis Patients. Semin Dial. 25(5): 491-494.
  13. Garcia-Prats AJ, Schaaf HS, Hesseling AC. (2016). The safety and tolerability of the second-line injectable antituberculosis drugs in children. Expert Opinion on Drug Safety. 15(11): 1491-1500.
  14. Dhouib IE, Jallouli M, Annabi A et al. (2016) A minireview on N-acetylcysteine: An old drug with new approaches. Life sciences. 151: 359-363.
  15. Gu WJ, Wu ZJ, Wang PF, Aung LHH, Yin RX. (2012). N-Acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trials. BMC Cardiovasc Disord. 12(1): 10.
  16. Liu XH, Xu CY, Fan GH. (2014). Efficacy of N-acetylcysteine in preventing atrial fibrillation after cardiac surgery: a meta-analysis of published randomized controlled trials. BMC Cardiovasc Disord. 14(1): 52.
  17. Colak N, Nazli Y, Alpay MF et al. (2013). Effect of topical N-acetylcysteine in the prevention of postoperative pericardial adhesion formation in a rabbit model. Cardiovascular Pathology. 22(5): 368-372.
  18. Masha A, Martina V. (2014). Endothelial dysfunction in metabolic diseases: role of oxidation and possible therapeutic employment of N-acetylcysteine. Curr Med Chem. 21(32): 3616-3635.
  19. Amaral EP, Conceição EL, Costa DL et al. (2016). N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions. BMC microbiology. 16(1): 251.
  20. Dasenbrook EC Chmiel JF. (2017). Anti-Inflammatory Therapies for Cystic Fibrosis, in Treatment of Cystic Fibrosis and Other Rare Lung Diseases. Springer. 139-151.
  21. Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. (2017). Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respiratory Research. 18(1): 26.
  22. Dekhuijzen P. (2004). Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 23(4): 629-636.
  23. Atalay F, Odabasoglu F, Halici M et al. (2016). N-Acetyl Cysteine Has Both Gastro-Protective and AntiInflammatory Effects in Experimental Rat Models: Its Gastro-Protective Effect is Related to its in Vivo and in Vitro Antioxidant Properties. J Cell Biochem. 117(2): 308-319.
  24. Shi X, Li D, Deng Q et al. (2016). Acetoacetic acid induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes. J Dairy Res. 83(4): 442-446.
  25. Slattery J, Kumar N, Delhey L et al. (2015). Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 55: 294-321.
  26. Miyake N, Miyamoto S. (2016). Effectiveness of N-acetylcysteine in the treatment of schizophrenia. Nihon shinkei seishin yakurigaku zasshi. J Clin Psychopharmacol. 36(2): 29.
  27. Zavodnick AD, Ali R. (2014). N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review. Psychiatric Quarterly. 85(2): 177-185.
  28. Farokhnia M, Azarkolah A, Adinehfar F et al. (2013). N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 36(6): 185-192.
  29. Santos P, Herrmann AP, Benvenutti R et al. (2017). Anxiolytic properties of N-acetylcysteine in mice. Behavioural brain research. 317: 461-469.
  30. Mocelin R, Herrmann AP, Marcon M et al. (2015). N-acetylcysteine prevents stress-induced anxiety behavior in zebrafish. Pharmacology Biochemistry and Behavior. 139: 121-126.
  31. Berk M, Dean OM, Cotton SM et al. (2014). The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. The Journal of clinical psychiatry. 75(6): 628-636.
  32. Oliver G, Dean O, Camfield D et al. (2015). N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci. 13(1): 12-24.
  33. Minarini A, Ferrari S, Galletti M et al. (2017). N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin Drug Metab Toxicol. 13(3): 279-292.
  34. Martínez-Banaclocha M. (2016). Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine. Curr Drug Metab. 17(4): 368-385.
  35. Botsakis K, Theodoritsi S, Grintzalis K et al. (2016). 17β-Estradiol/N-acetylcysteine interaction enhances the neuroprotective effect on dopaminergic neurons in the weaver model of dopamine deficiency. Neuroscience. 320: 221-229.
  36. Thakker D, Raval A, Patel L, Walia, R. (2015). N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int. Article ID: 817849.
  37. Saha L, Kaur S, Saha PK. (2013). N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomes. JPP. 4(3): 187.
  38. Tras B, Dinc DA, Uney K. (2014). The effect of N-acetylcysteine on the treatment of clinical endometritis and pregnancy rate in dairy cows. Eurasian J Vet Sci 30(3): 133-137.
  39. Gores-Lindholm AR, LeBlanc MM, Causey R et al. (2013). Relationships between intrauterine infusion of N-acetylcysteine, equine endometrial pathology, neutrophil function, post-breeding therapy, and reproductive performance. Theriogenology. 80(3): 218-227.
  40. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. (2007). Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations. Can J Clin Pharmacol. 14: e246-e250.
  41. Miner SE, Dzavik V, Nguyen-Ho P et al. (2004). N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 148(4): 690-695.
  42. Anderson SM, Park ZH, Patel RV. (2011). Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy. Ann Pharmacother. 45(1): p. 101-107.
  43. Tepel M, Van Der Giet M, Schwarzfeld C. (2000). Prevention of radiographic-contrast-agent–induced reductions in renal function by acetylcysteine. N Engl J Med 343(3): 180-184.
  44. Wu MY, Hsiang HF, Wong CS. (2013). The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol 45(5): 1309-1318.
  45. Subramaniam RM, Suarez-Cuervo C, Wilson RF. (2016). Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy A Systematic Review and Meta-analysis. Ann Intern Med. 164(6): 406-416.
  46. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. (2004). The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 15(2): 407-410.
  47. Ozdil B, Cosar A, Akkiz H, Sandikci M, Kece C. (2011). New therapeutic option with N-acetylcysteine for primary sclerosing cholangitis: two case reports. Am J Ther 18(3): e71-e74.
  48. Hou Y, Wang L, Yi D, Wu G. (2014). N-acetylcysteine and intestinal health: a focus on its mechanism of action. Frontiers in bioscience (Landmark edition). 20: 872-891.
  49. Dabirmoghaddam P, Amali A, Langroudi MM et al. (2013). The Effect of N-Acetyl Cysteine on Laryngopharyngeal Reflux. Acta Medica Iranica. 51(11): 757.
  50. Neale JR, James S, Callaghan J, Patel P. (2013). Premedication with N-acetylcysteine and simethicone improves mucosal visualization during gastroscopy: a randomized, controlled, endoscopist-blinded study. Eur J Gastroenterol Hepatol. 25(7): 778-783.
  51. Chen MJ, Wang HY, Chang CW. (2013). The add-on N-acetylcysteine is more effective than dimethicone alone to eliminate mucus during narrow-band imaging endoscopy: a double-blind, randomized controlled trial. Scand J Gastroenterol. 48(2): 241-245.
  52. Wrotek S, Jędrzejewski T, Piotrowski J, Kozak W. (2016). N-Acetyl-l-cysteine exacerbates generation of IL-10 in cells stimulated with endotoxin in vitro and produces antipyresis via IL-10 dependent pathway in vivo. Immunology Letters. 177: 1-5.
  53. Prauchner CA. (2016). Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy. Burns. 43 (3): 471-485.
  54. García A, Salas-Jara MJ, Herrera C, González C. (2014). Biofilm and Helicobacter pylori: from environment to human host. World J Gastroenterol. 20(19): 5632-5638.
  55. Leite B, Gomes F, Teixeira P et al. (2013). Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin. Am J Ther. 20(4): 322-328.
  56. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. (2014). N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 18(19): 2942-8.
  57. Aslam S, Darouiche RO. (2011). Role of antibiofilm-antimicrobial agents in control of device-relate infections. Int J Artif Organs. 34(9): 752.
  58. Kashef N, Karami S, Djavid GE. (2015). Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms. Photodiagnosis Photodyn Ther. 12(2):186-192.
  59. Blasi F, Page C, Rossolini GM et al. (2016). The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 117:190-197.
  60. May ER, Conklin KA, Bemis DA. (2016). Antibacterial effect of N-acetylcysteine on common canine otitis externa isolates. Vet Dermatol. 27(3): 188-e47.
  61. Olofsson AC, Hermansson M, Elwing H. (2005). Use of a quartz crystal microbalance to investigate the antiadhesive potential of N-acetyl-L-cysteine. Appl Environ Microbiol. 71(5): 2705-2712.
  62. Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. (1999). The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 43(2): 107-113.
  63. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. (2000). Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration. 67(5): 552-558.
  64. Homa M, Galgóczy L, Tóth E et al. (2016). In vitro susceptibility of Scedosporium isolates to N-acetyl-L-cysteine alone and in combination with conventional antifungal agents. Med Mycol. 54 (7): 776-779.
  65. Geiler J, Michaelis M, Naczk P et al. (2010). N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 79(3): 413-420.
  66. Lasram MM, Dhouib IB, Annabi A, El Fazaa S, Gharbi N. (2015). A review on the possible molecular mechanism of action of N-acetylcysteine against insulin resistance and type-2 diabetes development. Clin Biochem. 48(16): 1200-1208.
  67. AlMatar M, Batool T, Makky EA. (2016). Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects. Curr Drug Metab. 17(2): 156-167.